Skip to main content

Advertisement

Table 1 Clinical and radiologic characteristics of patients with intermediate to advanced hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE) with or without H101

From: Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study

Variable Overall [cases (%)] TACE group [cases (%)] TACE with H101 group [cases (%)] P value
Age (years)     0.420
 ≤60 337 (70.8) 164 (68.9) 173 (72.7)  
 >60 139 (29.2) 74 (31.1) 65 (27.3)  
Sex     0.877
 Man 430 (90.3) 214 (89.9) 216 (90.8)  
 Woman 46 (9.7) 24 (10.1) 22 (9.2)  
WBC (×109/L)     0.693
 <10 449 (94.3) 223 (93.7) 226 (95.0)  
 ≥10 27 (5.7) 15 (6.7) 12 (5.0)  
PLT (×109/L)     0.123
 <100 58 (12.2) 35 (14.7) 23 (9.7)  
 ≥100 418 (87.8) 203 (85.3) 215 (90.3)  
ALT (U/L)     0.682
 <40 173 (36.3) 79 (33.2) 94 (39.5)  
 ≥40 303 (63.7) 159 (66.8) 144 (60.5)  
AST (U/L)     0.924
 <45 168 (35.3) 83 (34.9) 85 (35.7)  
 ≥45 308 (64.7) 155 (65.1) 153 (64.3)  
ALB (g/L)     0.417
 <35 63 (13.2) 35 (14.7) 28 (11.8)  
 ≥35 413 (86.8) 203 (85.3) 210 (88.2)  
TBIL (mmol/L)     0.066
 <20 381 (80.0) 182 (76.5) 199 (83.6)  
 ≥20 95 (20.0) 56 (23.5) 39 (16.4)  
IBIL (mmol/L)     0.011
 <15 431 (90.5) 207 (87.0) 224 (94.1)  
 ≥15 45 (9.5) 31 (13) 14 (5.9)  
ALP (U/L)     0.773
 <100 166 (34.9) 81 (34.0) 85 (35.7)  
 ≥100 310 (65.1) 157 (66.0) 153 (64.2)  
CRP (mg/L)     0.714
 <8.2 249 (52.3) 127 (53.4) 122 (51.2)  
 ≥8.2 227 (47.7) 111 (46.6) 116 (48.8)  
AFP (ng/mL)     0.923
 <25 164 (34.5) 81 (34.0) 83 (34.8)  
 ≥25 312 (65.5) 157 (66.0) 155 (65.2)  
HBsAg     0.046
 Negative 27 (5.7) 19 (8.0) 8 (3.4)  
 Positive 449 (94.3) 219 (92.0) 230 (96.6)  
HBV-DNA (IU/mL)     0.589
 <100 112 (23.5) 59 (24.8) 53 (22.2)  
 ≥100 364 (76.5) 179 (75.2) 185 (77.8)  
NLR     0.916
 <3 354 (74.4) 178 (74.8) 176 (73.9)  
 ≥3 122 (25.6) 60 (25.2) 62 (26.1)  
Tumor size (cm)     1.000
 <5 130 (27.3) 65 (27.3) 65 (27.3)  
 ≥5 346 (72.7) 173 (72.7) 173 (72.7)  
Tumor number     0.391
 Single 172 (36.1) 91 (38.2) 81 (34.0)  
 Multiple 304 (63.9) 147 (61.8) 157 (66.0)  
Splenomegaly     0.177
 No 311 (65.3) 148 (62.2) 163 (68.5)  
 Yes 165 (34.7) 90 (37.8) 75 (31.5)  
Metastasis     0.835
 No 452 (95.0) 227 (95.4) 225 (94.5)  
 Yes 24 (5.0) 11 (4.6) 13 (5.5)  
Vascular invasion     0.763
 No 336 (70.6) 170 (71.4) 166 (69.7)  
 Yes 140 (29.4) 68 (28.6) 72 (30.3)  
Antiviral therapy     0.066
 No 251 (52.7) 115 (48.3) 136 (57.1)  
 Yes 225 (47.3) 123 (51.7) 102 (42.9)  
  1. WBC white blood cell count, PLT platelet, ALT alanine transaminase, AST aspartate aminotransferase, ALB albumin, TBIL total bilirubin, IBIL indirect bilirubin, ALP alkaline phosphatase, CRP C-reactive protein, AFP alpha-fetoprotein, HBsAg surface antigen of hepatitis B virus, HBV hepatitis B virus, NLR neutrophil-to-lymphocyte ratio